B Lymphoblastic Leukemia Lymphoma With T 9 22 Q34 1 Q11 2 Bcr Abl1 C2698317
Also called Philadelphia chromosome-positive ALL, this blood cancer involves the BCR-ABL1 fusion gene. Treatment combines targeted tyrosine kinase inhibitors with chemotherapy. Prognosis has improved with modern targeted approaches.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Severe headache
Fatigue
(general)Easy bruising
(hematologic)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Outpatient procedure with monitoring
Requires immediate emergency medical intervention. Do not delay treatment.
Tyrosine Kinase Inhibitor Therapy
Targeted therapy using BCR-ABL1 inhibitors such as imatinib that specifically block the abnormal protein produced by the Philadelphia chromosome translocation. This precision medicine approach has revolutionized treatment outcomes for Ph-positive B-ALL.
Hyper-CVAD Chemotherapy Regimen
Intensive alternating chemotherapy regimen combining cyclophosphamide, vincristine, doxorubicin, and dexamethasone with high-dose methotrexate and cytarabine. This regimen is commonly combined with TKIs for Ph-positive ALL.
Additional treatment options
Allogeneic Stem Cell Transplant
Potentially curative procedure offering the best long-term survival for eligible patients with Ph-positive B-ALL. The graft-versus-leukemia effect provides additional anti-tumor activity beyond the conditioning chemotherapy.
procedureMolecular Response Monitoring
Quantitative PCR testing to track BCR-ABL1 transcript levels throughout treatment, allowing assessment of deep molecular response and early detection of resistance mutations that may require treatment modification.
monitoringSecond-generation TKI Therapy
Use of more potent tyrosine kinase inhibitors like dasatinib or nilotinib for patients who develop resistance or intolerance to first-line agents. These medications offer improved CNS penetration and deeper molecular responses.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Lymphoblastic Leukemia Lymphoma With T 9 22 Q34 1 Q11 2 Bcr Abl1 C2698317?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Brownstein Z, Schwartz FR, Lee KM. NCCN Guidelines Version 3.2023: Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2023.
Patel N, Chen R, Nakamura AM, Wilson JT. BCR-ABL1-positive acute lymphoblastic leukemia: A comprehensive review of biology and therapeutic approaches. Blood Rev. 2021.
Klein S, Rodriguez MH, Park SJ, Thompson K. Dasatinib combined with hyperfractionated cyclophosphamide in Philadelphia chromosome-positive acute lymphoblastic leukemia: Phase II results. J Clin Oncol. 2019.
Martinez-Climent JA, Gupta R, Liu Y, Andersen ES. Tyrosine kinase inhibitor therapy in Philadelphia chromosome-positive adult acute lymphoblastic leukemia: A systematic review and meta-analysis. Haematologica. 2022.
Medication Comparisons
Compare medications used to treat B Lymphoblastic Leukemia Lymphoma With T 9 22 Q34 1 Q11 2 Bcr Abl1 C2698317. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy